Código 3002 (Harmonized System 2012 by 4 digits)
2023: US$2.28B, Total Trade Exchange
2023: US$203M, International Sales
2023: US$2.08B, International Purchases
In 2023, the trade exchange (includes international purchases and sales) of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes was US$2.28B.
In 2023, the states with the most international sales in Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes were Estado de México (US$86.1M), Ciudad de México (US$39.1M), Baja California (US$37.8M), Jalisco (US$31.9M), and Sonora (US$1.26M).
The states with the most international purchases in 2023 were Ciudad de México (US$1.69B), Estado de México (US$293M), Jalisco (US$36.7M), Baja California (US$33.7M), and Morelos (US$12.8M).
In 2023, the main commercial destinations of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes were France (US$84.6M), United States (US$51.6M), Guatemala (US$6.37M), Belgium (US$5.94M), and Dominican Republic (US$5.65M).
The main commercial origins of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes in 2023 were United States (US$378M), Switzerland (US$271M), Germany (US$263M), Puerto Rico (US$204M), and France (US$190M).
In the global context, the main exporting countries of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes in 2022 were Ireland (US$47.3B), United States (US$46.8B), and Belgium (US$46.5B). In the same year, the main importing countries of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes were United States (US$67.8B), Germany (US$40.9B), and Belgium (US$21.6B).
US$2.28B, Total Trade Exchange (2023)
In 2023, the total trade exchange of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes in Mexico (including international purchases and sales) was US$2.28B.
The visualizations show the net balance of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
November, 2024
In November 2024, international sales of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes were US$6.23M, while international purchases reached US$235M. The above results in a trade balance of -US$229M.
2024-Q4: US$12.3M, International Sales
The visualization shows the quarterly concentration of international sales of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes at state level.
In the fourth quarter of 2024, international sales were US$12.3M, being the states with the most sales Ciudad de México (US$5.69M), Jalisco (US$4.69M), and Baja California (US$1.56M).
Estado de México: US$86.1M, State with the Most International Sales (2023)
France: US$84.6M, Main commercial destination (2023)
In 2023, the states with the highest international sales in Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes were Estado de México (US$86.1M), Ciudad de México (US$39.1M), Baja California (US$37.8M), Jalisco (US$31.9M), and Sonora (US$1.26M).
In 2023, the countries with the most international purchases from Mexico were France (US$84.6M), United States (US$51.6M), Guatemala (US$6.37M), Belgium (US$5.94M), and Dominican Republic (US$5.65M).
Ciudad de México: US$1.69B, State with the Most International Purchases (2023)
United States: US$378M, Main Commercial Origin (2023)
In 2023, the states with the highest international in Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes were Ciudad de México (US$1.69B), Estado de México (US$293M), Jalisco (US$36.7M), Baja California (US$33.7M), and Morelos (US$12.8M).
The countries with the most international sales to Mexico in 2023 were United States (US$378M), Switzerland (US$271M), Germany (US$263M), Puerto Rico (US$204M), and France (US$190M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes were Ireland (US$47.3B), United States (US$46.8B), and Belgium (US$46.5B). In the same year, the main importing countries for Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes were United States (US$67.8B), Germany (US$40.9B), and Belgium (US$21.6B).